Oncternal Therapeutics Stock Net Income
| ONCT Stock | USD 0.71 0.43 37.72% |
Oncternal Therapeutics fundamentals help investors to digest information that contributes to Oncternal Therapeutics' financial success or failures. It also enables traders to predict the movement of Oncternal Stock. The fundamental analysis module provides a way to measure Oncternal Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncternal Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -39.5 M | -41.5 M | |
| Net Loss | -41.7 M | -43.8 M | |
| Net Loss | -50.8 M | -53.3 M | |
| Net Loss | (13.43) | (14.10) | |
| Net Income Per E B T | 1.13 | 1.24 |
Oncternal | Net Income |
Oncternal Therapeutics Company Net Income Analysis
Oncternal Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Oncternal Therapeutics Net Income | (39.48 M) |
Most of Oncternal Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncternal Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oncternal Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncternal Therapeutics is extremely important. It helps to project a fair market value of Oncternal Stock properly, considering its historical fundamentals such as Net Income. Since Oncternal Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncternal Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncternal Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Oncternal Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Oncternal Therapeutics reported net income of (39.48 Million). This is 111.57% lower than that of the Biotechnology sector and 156.36% lower than that of the Health Care industry. The net income for all United States stocks is 106.91% higher than that of the company.
Oncternal Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncternal Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncternal Therapeutics could also be used in its relative valuation, which is a method of valuing Oncternal Therapeutics by comparing valuation metrics of similar companies.Oncternal Therapeutics is currently under evaluation in net income category among its peers.
Oncternal Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Oncternal Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oncternal Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oncternal Therapeutics' value.| Shares | Wells Fargo & Co | 2024-06-30 | 300 | North Star Investment Management Corp | 2024-09-30 | 250 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 182 | Advisor Group Holdings, Inc. | 2024-06-30 | 150 | U.s. Bancorp | 2024-06-30 | 100.0 | Ubs Group Ag | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 22.0 | Steward Partners Investment Advisory, Llc | 2024-06-30 | 15.0 | Lindbrook Capital, Llc | 2024-09-30 | 15.0 | Vanguard Group Inc | 2024-09-30 | 139.9 K | Millennium Management Llc | 2024-06-30 | 102.9 K |
Oncternal Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (17.57) % | ||||
| Current Valuation | (12.29 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 12.07 % | ||||
| Number Of Shares Shorted | 45.35 K | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.23 X | ||||
| Price To Sales | 0.97 X | ||||
| Revenue | 785 K | ||||
| Gross Profit | (31.49 M) | ||||
| EBITDA | 2.23 M | ||||
| Net Income | (39.48 M) | ||||
| Cash And Equivalents | 78.9 M | ||||
| Cash Per Share | 1.48 X | ||||
| Total Debt | 318 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.78 X | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (32.16 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (11.69) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 2.1 M | ||||
| Total Asset | 36.73 M | ||||
| Retained Earnings | (197.78 M) | ||||
| Working Capital | 30.86 M | ||||
| Current Asset | 27.27 M | ||||
| Current Liabilities | 6.3 M | ||||
| Net Asset | 36.73 M |
About Oncternal Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncternal Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncternal Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncternal Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.